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Summary Chimeric antigen receptor (CAR) T cell
therapy has been established in the treatment of
hematological malignancies. However, in solid tu-
mors its efficacy remains limited. The aim of this
article is to give an overview of the field of cell ther-
apy itself, to introduce the underlying concepts of
CAR T cell-based treatment approaches and to ad-
dress its limitations in advancing the treatment for
solid malignancies.
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Background
Over the last decade, treatment of cancer has under-
gone a radical paradigm shift. Targeted therapies, ei-
ther utilizing tyrosine kinase inhibitors (TKI) or ther-
apeutic antibodies, have developed into integral el-
ements of oncological treatment regimes. In con-
trast, cellular therapies are merely starting to enter
clinical routine [1]. Of these, T cell-based methods,
also known as adoptive T cell therapy (ACT), are the
most advanced. ACT aims to combine the extraordi-
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nary specificity of the adaptive immune system and
the natural antitumor response of T cells in the fight
against cancer. To date, depending on the source of
the T cells and the subsequent genetic or nongenetic
manipulation, three main forms of T cell-based ther-
apies can be distinguished:
 Tumor-infiltrating lymphocytes (TIL),
 T cell receptor (TCR)-engineered T cells and
 Chimeric-antigen receptor (CAR) T cells [2].
TIL are T cells, found in the tumor tissue, which in
most cases are equipped with endogenous TCR spe-
cific for tumor-associated antigens. In TIL-based ACT,
these T cells are isolated from surgical tumor speci-
mens, are expanded in vitro and re-infused into the
patients [3]. However, one major limitation to this
approach is the often low number of antigen-specific
T cells found in tumor explants and the inability to
retrieve and expand T cells from all patients. To over-
come these limitations, in vitro engineering methods
have been developed to create antigen-specific T cells
without needing to isolate them from tumor tissues.
As such, naïve, unspecific T cells are isolated from
the peripheral blood of the patients via leukapheresis,
are then genetically modified with a tumor-specific
recognition construct (e.g., tumor-specific TCR, CAR),
expanded and finally re-infused into the patient [4].
TCR-engineered T cells and CAR T cells
As described, TCR T cells are genetically modified to
express an antigen-specific TCR. In the treatment of
neoplastic diseases, the target is usually a tumor-spe-
cific antigen (TSA) or tumor-associated antigen (TAA).
Ideally, these would be uniquely expressed in malig-
nant cancer cells, but not in healthy cells. Peptides
derived from TSA are generated through intracellular
proteasome-mediated processing mechanisms and
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subsequently presented on the MHC-I complex of
the tumor cells [2]. TCR-engineered T cells are able
to recognize the MHC-TSA-peptide complex, which
leads to an activation of T cells and subsequent ly-
sis of neoplastic cells. In contrast, CAR T cells are
engineered through introduction of an artificial syn-
thetic construct, which ultimately also leads to the
activation of the T cells and tumor cell lysis [2]. Both
strategies have certain advantages and disadvantages,
which have been extensively reviewed elsewhere [2,
5].
The artificial CAR construct usually contains an an-
tibody-derived single-chain variable fragment (scFv)
as an extracellular domain, a hinge domain and
a transmembrane domain, anchoring the receptor
in the cell membrane. T cells expressing the con-
struct are able to bind the respective TSA via the
extracellular antibody-derived scFv domain of the
CAR receptor. Activation of T cells is subsequently in-
duced by an intracellularly located signaling domain,
consisting of a CD3ζ chain and one or more co-stim-
ulatory domains (e.g., CD28, 4-1BB) [2]. The CD3ζ
chain is physiologically part of the TCR-CD3 complex
and is the major inducer of T cell activation following
antigen recognition. Co-stimulatory domains were
included in the second and third generations of CAR
constructs, as augmented antitumor efficacy [6] and
increased persistence of the transferred T cells [7] has
been observed. Depending on the CAR receptor used,
CAR T cells are classified in different generations, as
depicted in Fig. 1.
In recent years, further improvements of the CAR
structures have been employed in order to improve ef-
ficacy of CAR T cells, especially in solid malignancies
(see “CAR T cells in solid tumors” section). These in-
novative approaches have been extensively reviewed
by us and other groups and interested readers are
Fig. 1 Structure and classification of CAR T cells. CAR
T cells are grouped into different generations depending on
the structure of the CAR. Recent advancements have added
new CAR structures, which are extensively reviewed in [5, 8].
scFv single chain variable fragment, CD3ζ CD3 zeta chain, IL-
2R β Chain IL-2 receptor β chain
referred to the following literature for a more detailed
overview [5, 8]. In short, fourth-generation CAR con-
structs incorporate a cassette into the intracellular
domain to induce the secretion of pro-inflammatory
cytokines. This strategy enables the innate immune
system to contribute to the antitumor effect (Table 1;
[9]). In contrast, fifth-generation CAR T cells followed
a completely different approach and aimed to activate
the Janus kinase-signal transducers and activators of
transcription (JAK-STAT) signaling pathway to pro-
mote T cell proliferation. Fifth-generation CAR T cells
were shown to have superior antitumor effect and
persistence compared to second- and third-genera-
tions [10]. However, these developments are merely at
the beginning and not part of the clinical routine. All
U.S. Food & Drug Administration (FDA)- or European
Medicines Agency (EMA)-approved ACT strategies are
second-generation CAR-based approaches and only
approved for the treatment of certain hematological
malignancies.
CAR T cells in hematological malignancies
Axicabtagene ciloleucel and Tisagenlecleucel, both
approved in 2017 by the FDA and in 2018 by the EMA,
are CAR T cells engineered to target the B cell lineage
antigen CD19. CD19 is exclusively expressed on both
healthy and malignant B cells. Consequently, these
CAR T cells can be used to treat B cell malignan-
cies such as diffuse large B cell lymphomas (DLBCL)
and B cell acute lymphoblastic leukemia (B-ALL, only
Tisagenlecleucel). Approval was granted after aston-
ishing initial response rates of up to 93% in ALL and
54% in DLBCL were observed [5]. Importantly, these
response rates were reached in extensively pretreated
patients with chemotherapy-refractory or relapsed
malignant disease and many were durable [2]. A third
T cell product was just recently approved by both the
FDA and the EMA for the treatment of mantle cell
lymphoma (MCL; Tecartus, brexucabtagene autoleu-
cel) (NCT02601313) [11]. Recent long-term follow-
up studies revealed sustained response rates in pa-
tients. However, disease relapse is seen in up to 41%
of patients suffering from ALL [12]. In contrast, re-
sponse rates in DLBCL seems to be more durable as
the majority of responding patients do not experi-
ence relapse during the 12-month follow-up period
[5, 13]. In summary, CAR T cell therapy has emerged
as an important therapeutic option for hematolog-
ical malignancies. However, in nonhematological
malignancies CAR T cell therapy has so far failed to
demonstrate comparable treatment responses.
CAR T cells in solid tumors
Encouraged by the striking results seen in DLBCL
and ALL, new CAR T cells targeting different epithe-
lial antigens were developed and clinically tested.
As such, CAR-based ACT was evaluated in differ-
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Table 1 Published clinical trials in solid tumors







NCT01869166 Biliary tract cancer 2018 EGFR I 19 1/17 complete remission
10/17 stable disease
[36]
NCT02349724 CRC 2017 CEA I 10 7/10 stable disease [15]
NCT01212887 GI tumors 2017 CEACAM5 I 14 No objective clinical response
Terminated due to safety concerns
[37]
NCT02541370 GI tumors 2018 CD133 I 23 3/23 partial response
14/23 stable disease
[38]
NCT00730613 Glioblastoma 2015 IL13Rα2 I 3 No objective clinical response [16]
NCT02209376 Glioblastoma 2017 EGFRvIII I 10 Not available due to surgical intervention [17]
NCT01109095 Glioblastoma 2017 HER-2/neu I 17 1/17 partial response
7/17 stable disease
[39]
NCT01454596 Glioblastoma 2019 EGFRvIII I 18 No objective clinical response [21]
NCT02395250,
NCT03146234
HCC 2020 GPC3 I 13 2/13 partial response,
1/13 stable disease
[40]
Park et al. Neuroblastoma 2007 L1-CAM I 6 1/6 stable disease then partial response [41]
Pule et al. Neuroblastoma 2008 GD2 I 11 4/8 evidence of regression [42]
NCT00085930 Neuroblastoma 2011 GD2 I 19 3/19 complete remission [43]
NCT01822652 Neuroblastoma 2017 GD2 I 11 5/11 stable disease [44]
NCT01869166 NSCLC 2016 EGFR I 11 2/11 partial response
5/11 stable disease
[18]
Kershaw et al. Ovarian Carci-
noma
2006 FRα I 14 No objective clinical response [45]
NCT01897415 PDAC 2018 MSLN I 6 2/6 stable disease [46]
NCT01869166 PDAC 2020 EGFR I 14 4/14 partial response
8/14 stable disease
[14]
Junghans et al. Prostate cancer 2016 PSMA I 5 (6) 2/5 partial response [47]
Lamers et al. RCC 2016 CAIX I 12 No objective clinical response [48]
NCT00902044 Sarcomas 2015 HER-2/neu I 17 (19) 4/17 stable disease [49]
NCT02159716 Solid tumors 2019 MSLN I 15 11/15 stable disease [50]
CRC Colorectal Carcinoma, GI tumor, Gastrointestinal Tumor, HCC Hepatocellular Carcinoma, NSCLC Non-Small Cell Lung Cancer, PDAC Pancreatic Ductal Adeno-
carcinoma, RCC Renal Cell Carcinoma, IL13Ra2 Interleukin-13 receptor subunit alpha 2, L1-CAM L1 Cell Adhesion Molecule, HER2/neu Human epidermal growth
factor receptor 2, EGFR(vIII) Epidermal Growth Factor Receptor (variant III), CEACAM5 Carcinoembryonic antigen-related cell adhesion molecule 5, MSLN Mesothe-
lin, CEA Carcino-Embryonic Antigen, GPC3 Glypican-3, CAIX Carboxyanhydrase-IX, FRα α-folate Receptor, PSMA Prostate-specific membrane antigen
ent gastrointestinal malignancies (pancreatic can-
cer, NCT01869166; colorectal cancer, NCT02349724)
[14, 15], glioblastoma (NCT00730613; NCT02209376)
[16, 17] and non-small cell lung cancer (NSCLC,
NCT01869166) [18]. Table 1 gives a summary of al-
ready conducted clinical trials in solid malignancies.
Treatment and outcomes of patients suffering from
carcinomas, per definition derived from epithelial tis-
sues, however, differs from the treatment of hemato-
logical malignancies. To at least some extent, target
antigens are usually co-expressed on healthy tissues
[5]. Application of anti-CD19 CAR T cells for example
can lead to sustained B cell aplasia. In the clinical
setting however, this is not a life-threatening side ef-
fect and can be managed with regular substitution of
immunoglobulins [19]. In comparison, in solid ma-
lignancies the target antigen can be expressed at low
levels on other epithelial cells (e.g., lung, heart) and
thus potentially lead to serious adverse effects, as ob-
served by Morgan et al. [20]. Furthermore, high-dose
treatment with CAR T cells against an epithelial cell
antigen (EGFRvIII) has also been reported to lead to
the congestion of pulmonary vasculature and lethal
respiratory failure (NCT01454596) [21].
As a consequence, several newly initiated clinical
trials have primarily focused on the safety of the newly
developed CAR T cells, directed against various tar-
get antigens of solid tumors (e.g., EGFRvIII, MUC-1,
MAGE, CEA, GD2, CA125, MSLN; Table 1; [22]). These
studies were most often conducted in malignancies
with poor overall survival such as glioblastoma and
pancreatic ductal adenocarcinoma; however, as de-
picted in Table 1, therapies are assessed in a wide
range of different solid malignancies. While most
treatments were shown to be safe, the overall response
rates observed in these trials, especially compared to
the impressive clinical benefit obtained in ALL and
DLBCL, were rather disappointing. Overall mortality
remained approximately the same and the patients
usually only benefited from the treatment temporarily
[8].
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Hurdles of CAR T cell therapy in solid tumors
As described above the responsiveness of solid malig-
nancies to CAR T cell therapy is bleak at best.
Over the last years, researchers have identified sev-
eral underlying mechanisms responsible for the lack
of treatment efficacy in solid tumors and have identi-
fied threemajor hurdles: (1) trafficking of T cells as the
first key limiting step, (2) the choice of target antigen
and antigen loss (tumor cell recognition) and (3) the
hostile tumor microenvironment [8].
Trafficking of the transferred T cells into solid tu-
mors is a limiting factor dampening therapeutic effi-
cacy. As such, different strategies have been applied to
improve T cell trafficking into the tumors. Direct ap-
plication (intratumoral injection) of T cells has been
employed to directly deliver the CAR T cells to the
tumor site (NCT00730613) [16]. The need for inva-
sive interventional procedures as well as the often
inaccessible tumors however limit these approaches.
Alternative strategies make use of physiological pro-
cesses of immune cell trafficking: Immune cell re-
cruitment to the site of inflammation is mediated by
the chemokine–chemokine receptor axis. High levels
of chemokine ligands secreted at the site of inflamma-
tion lead to the recruitment of immune cells express-
ing matching receptors. As solid tumors tend to show
enhanced levels of chemokine ligands, co-transduc-
tion of chemokine receptors commonly not present
on T cells, and CAR receptors into T-cells, has been
employed by us and another groups [23, 24]. This has
been shown to enhance both T cell infiltration and
therapeutic efficacy in preclinical models. This con-
cept is currently under investigation in clinical trials
(NCT03602157).
Loss of the target antigen on tumor cells is a prob-
lem common in treatment of both hematological and
nonhematological malignancies. Relapse with CD19-
negative disease, for example, is frequently observed
after treatment with CD19 CAR T cells. In solid tu-
mors, down-regulation of the target antigen following
CAR T cell therapy has also been reported in different
clinical trials [17]. Targeting of multiple antigens (e.g.
CD19 plus CD20; CD19 plus CD22) or alternatively
sequential targeting strategies have shown benefit in
different clinical trials [25–27].
Finally, solid tumors exhibit a complex, often hos-
tile tumor microenvironment (TME). Besides cancer
cells, the TME of solid tumors comprises infiltrating
and resident immune cells, stromal cells as well as
many pro- and anti-inflammatory mediators [28]. The
interactions between the different components of the
TME are complex and cannot be described in detail
here. For further information please see the follow-
ing literature [28–30]. In general, the components of
the TME suppress an appropriate immune response
against cancer cells, thus, creating a conducive envi-
ronment for the tumor cells to proliferate.
The nowadays commonly used checkpoint in-
hibitors (e.g., pembrolizumab, nivolumab, ipilimu-
mab) boost the activation and function of T cells
through blockade of inhibitory receptors on T cells
(e.g., PD-1, CTLA-4). As such, combining CAR T cells
with immune checkpoint inhibitors or other drugs
influencing the immunosuppressive nature of the
TME are currently being investigated [8]. In addition,
genetic engineering can be employed to lift immune-
suppressive effects on the transferred T cells. Our
group has developed a fusion receptor, switching the
inhibitory signal of PD-1 into a T cell activating signal
[31]. Alternatively, CRISPR-Cas9-mediated disruption
of the PD-1 locus in CAR T cells has been shown to
increase therapeutic efficacy of CAR T cells in vitro
and in vivo. Several clinical trials are currently investi-
gating these strategies (NCT03081715, NCT02867332,
NCT02867345, NCT02793856, NCT03044743) [32].
Lastly, preclinical research has demonstrated the
feasibility of redirecting CAR T cells not against tu-
mor cells, but at immunosuppressive cells in the tu-
mor microenvironment. Thus, CAR T cells target-
ing cancer-associated fibroblasts or tumor-associated
macrophages have been shown to delay cancer pro-
gression in preclinical mouse models [33, 34]. How-
ever, to date no clinical data on these strategies are
available, so the value remains uncertain.
Conclusion
The clinical transition of CAR T cell therapy has
started a new era in oncology. Although these ap-
proaches have already given hope to incurable cancer
patients suffering from hematological malignancies,
it still remains to be proven in the comprehensive
field of solid malignancies. As one might infer from
our short overview, glioblastoma was often targeted
in clinical studies. Due to limitations arising from
its anatomical location and quick progression rate,
glioblastoma remains clinically challenging to this
date. Even a tumor as aggressive as glioblastoma was
reported to be fully regressed in a case collection by
Brown et al. [35]. The overall results of clinical stud-
ies might seem disappointing, but such case reports
highlight the potential of CAR T cell therapy in solid
cancers and maybe give a glimpse into what can be
achieved in the future. Consequent advancement of
promising preclinical strategies into clinical testing is
now crucial to broaden the scope of cellular therapies
and to increase the efficacy in solid tumors, with the
hope that these therapies will not only be effective
in single patients, but present a real clinical alterna-
tive for so many incurable cancer patients in daily
oncological routine.
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Take home message
 Adoptive T cell therapy has emerged has an impor-
tant treatment option in relapsed and chemotherapy-
refractory hematological malignancies.
 Clinical trials in solid tumors have primarily focused
on establishing the safety of CAR T cell therapy; how-
ever, secondary endpoint analyses have so far only
revealed modest efficacy.
 Preclinical research has been able to identify major
caveats of CAR T cell therapy in solid tumors. Clini-
cal trials will now have to determine whether this can
be translated into clinically relevant improvements in
patient outcome.
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